I don't have the actual numbers, but Dendreon's market for Provenge is a lot larger than PRR's market for CVAC, so it cannot be valued to worth the same as Dendreon on the one product.
When factoring in Oral Giardasil, CVAC for Breast cancer, and other indications (approx $1.5Bn per indication), PRR would have a total market substantially larger than DNDN.
This has been discussed over the years... the info is out there - apologies I can't recal exact number and when things have been discussed.
nasdaq listing, page-12
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |